Boryung (previously Boryung Pharmaceutical) goes all out for the home launch of Finjuve Spray, or “sprinkling Propecia,” a hair loss therapy based mostly on finasteride.
Boryung plans to launch Finjuve Spray subsequent March or April, leaping into the home hair loss therapy market as early as the primary quarter of subsequent yr.
Finjuve Spray is a hair loss therapy Boryung introduces in Korea below an unique gross sales contract with the worldwide pharmaceutical firm Almirall. It obtained a license from the Ministry of Food and Drug Safety in September. Its indication is treating “gentle to average male alopecia (androgen alopecia) in grownup males (18-41 years outdated).
It turned MSD’s unique drug Propecia and its finasteride ingredient into spray formulation. All earlier finasteride remedies, together with Propecia, are oral varieties.
“Generally, users have to administer it for three to six months to see treatment effectiveness, and we recommend continuous administration after that to maintain the effects,” the Ministry of Food and Drug Safety mentioned. “There are no clinical trial experiences for its administration for six months or more.”
Boryung can also be making strenuous efforts to defend towards generics earlier than the product’s launch. It registered Finjuve Spray on the patent listing of medicinal merchandise on Tuesday.
Industry watchers are taking note of Finjuve Spray, questioning whether or not it will possibly attain noticeable ends in competitors towards Propecia and the complete hair loss therapy market.